‘Glue ear’ treatment could see ‘end to grommet surgery’
Baku, October 25 (AZERTAC). Scientists have identified a potential new treatment for “glue ear” - a common hearing disorder in children - that uses existing cancer drugs.
Writing in PLoS Genetics, researchers from the Medical Research Council found that these drugs relieved the symptoms of persistent ear inflammation in mice.
They say the discovery could lead to an alternative to grommet surgery for many children.
A hearing loss charity said it was an important step towards a new treatment.
The study says that several existing drugs currently used in cancer treatment, known as VEGF inhibitors, can tackle the root causes of ‘glue ear’.
Prof Steve Brown, director of the MRC mammalian genetics unit at the Medical Research Council and lead study researcher, said that a lack of oxygen reaching the middle ear was a key factor in the development of the condition.
The researchers say they want to “repurpose” the cancer drugs into a treatment which can be delivered directly into the ear at the area of inflammation.
They claim this will help to eliminate any potential side-effects of the drugs.
“The next stage involves looking in more detail at how to apply this in humans and children,” Professor Brown said.
“We wouldn’t normally want to give anti-cancer drugs to children, but the middle ear is relatively accessible and a GP could put a patch directly on the membrane in the middle ear.”
He also said it would be a non-invasive, non-surgical treatment.
Currently, NICE recommends grommets or hearing aids as effective treatments for glue ear which does not clear up over time.
Grommets are tiny plastic tubes which are put into the eardrum to improve ventilation during a short operation under general anaesthetic.
Around 30,000 grommet insertions are carried out each year in the UK.
Dr Ian Williamson, senior lecturer in general practice at the University of Southampton, expert in the field of otitis media and adviser to Deafness Research UK, said the study was a considerable scientific advance.
“Although the results published today are clearly ground-breaking, carefully controlled clinical trials would be needed before any new treatments would be available in the clinic or doctors surgery.”
Dr Ralph Holme, head of biomedical research at Action on Hearing Loss, said: “This research is an important step towards an effective pharmacological treatment for this common and distressing condition.”
The research was carried out by the MRC Mammalian Genetics Unit, the Mary Lyon Centre at Harwell and the University of Oxford.
Other news in this section
